SuperSonic Imagine Reports Sales Growth of +10% in Q3 2016
October 18 2016 - 12:00PM
Business Wire
- Solid growth in the United States
- Further significant growth in Service
sales
Regulatory News:
SuperSonic Imagine (Paris:SSI) (Euronext SSI, FR0010526814,
PEA-PME eligible), the highly innovative ultrasound company, today
announces its sales for the third quarter to September 30,
2016.
In thousands of euros
2016 2015
Change (%) Products 3,429 2,861 +20% Services
474 371 +28%
1st quarter sales
3,903 3,232 +21% Products 4,434
4,579 -3% Services 522 440 +18%
2nd quarter
sales 4,956 5,019 -1%
Products 5,175 4,759 +9% Services 519 440 +18%
3rd
quarter sales 5,694 5,199
+10% Products 13,038 12,199 +7% Services 1,515 1,251 +21%
9-month sales 14,553 13,450
+8% Other revenue* 1,023 1,278
-20% Total 9-month revenue 15,576 14,728 +6%
Unaudited data(*): this revenue is non recurrent by nature and
is not part of the Company’s core business.
In the 3rd quarter of 2016, SuperSonic Imagine recorded sales of
€5.7 million, up +10% compared with the 3rd quarter of 2015 (€5.2
million). At constant currency, growth was +9% between the two
periods. Sales for the first nine months of the year to September
30, 2016 were €14.6 million, up +8% compared with the same nine
months of 2015 (€13.4 million).
SuperSonic Imagine saw a +9% quarterly increase in sales of its
Aixplorer systems (+7% for the first nine months of the year) and a
+18% increase in Service sales (+21% for the first nine months of
the year). The growth in Service sales as of September 30, 2016,
was mainly driven by France and direct sales in the United
States.
In its priority markets, the geographical sales performance in
the quarter was led by the United States with growth of +15% and
+7% in China. Our three priority markets (China, United States and
France) generated 58% of total sales over the quarter and 62% over
the first nine months of the year.
Globally, as of September 30, 2016, an analysis of the Company’s
sales confirms the strategic choice implemented in 2015 that
consisted in refocusing on key indications (breast, liver) on its
three key geographies that are the United States (+5% with a +57%
jump in direct sales), China (+10%) and France (+13%).
Elisabeth Winter, Executive VP and Financial Director of
SuperSonic Imagine, says: “Over the third quarter, we generated a
growth level more in line with our goals and which we hope to
continue in the fourth quarter. It is traditionally the most
significant quarter in the imaging industry and this year will be
driven by the launch of a new version of Aixplorer® incorporating a
Fusion Navigation module.”
Other revenue essentially consists of fees to access the Group’s
technology. This revenue, which is non recurrent by nature, is not
included in the Company’s core revenue insofar as it is not part of
its core business.
About SuperSonic ImagineFounded in 2005 and based in
Aix-en-Provence (France), SuperSonic Imagine is a company
specializing in medical imaging. The company designs, develops and
markets a revolutionary ultrasound system, Aixplorer®, with an
UltraFast™ platform that can acquire images 200 times faster than
conventional ultrasound systems. In addition to providing
exceptional image quality, this unique technology is the foundation
of several innovations which have changed the paradigm of
ultrasound imaging: ShearWave™ Elastography (SWE™), UltraFast™
Doppler and more recently Angio PL.U.S – Planewave UltraSensitive™
Imaging. ShearWave Elastography allows physicians to visualize and
analyze the stiffness of tissue in a real-time, reliable,
reproducible and non-invasive manner. This criteria has become an
important parameter in diagnosing potentially malignant tissue or
other diseased tissue. As of today, over 300 peer-reviewed
publications have demonstrated the value of SWE for the clinical
management of patients with a wide range of diseases. UltraFast
Doppler combines Color Flow Imaging and Pulsed Wave Doppler into
one simple exam, providing physicians with exam results
simultaneously and helping to increase patient throughput. The
latest innovation, Angio PL.U.S, provides a new level of
microvascular imaging through significantly improved color
sensitivity and spatial resolution while maintaining exceptional 2D
imaging. SuperSonic Imagine has been granted regulatory clearances
for the commercialization of Aixplorer in key global markets.
SuperSonic Imagine is a listed company since April 2014 on the
Euronext, symbol SSI. For more information about SuperSonic
Imagine, please go to www.supersonicimagine.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161018006311/en/
SuperSonic ImagineBernard Doorenbos, +33 6 15 66 64
68CEObernard.doorenbos@supersonicimagine.comorNewCapInvestor
Relations – EUPierre Laurent / Florent Alba+33 1 44 71 98
55supersonicimagine@newcap.frorSuperSonic ImagineElisabeth
Winter, +33 6 61 45 69 17Finance Director, Executive
VPelisabeth.winter@supersonicimagine.comorPascale
CommunicationMedia Relations - USAmy Phillips, +1 412 327
9499amy@pascalecommunications.com
Stage Stores (NYSE:SSI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Stage Stores (NYSE:SSI)
Historical Stock Chart
From Mar 2023 to Mar 2024